Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

doi:10.4251/wjgo.v17.i4.103855

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2213)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

176

HTML

1065

Figures (1-2)

242

Tables (1-5)

197

Sum=1680

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

384

Sum=436

Apr 15, 2025 (publication date) through Nov 2, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103855
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103855

Open in New Tab Full Size Figure Download Figure

Figure 1 Comparison of objective response rate and disease control rate between control and observation groups, immunohistochemistry 3 + patients, and programmed death-ligand 1-positive patients, arranged in a grid format. A: Comparison of objective response rate (ORR) and disease control rate (DCR) between control and observation groups; B: Comparison of ORR and DCR for immunohistochemistry 3 + patients; C: Comparison of ORR and DCR for programmed death-ligand 1-positive patients. ORR: Objective response rate; DCR: Disease control rate; IHC: Immunohistochemistry; PD-L1: Programmed death-ligand 1.

Open in New Tab Full Size Figure Download Figure

Figure 2 Progression-free survival curves. A: The control and observation groups; B: Immunohistochemistry 3 + patients in the control and observation groups; C: Programmed death-ligand 1 expression in the observation group. PD-L1: Programmed death-ligand 1.

Citation: Zhang SH, Li W, Chen XY, Nie LL. Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients. World J Gastrointest Oncol 2025; 17(4): 103855
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103855.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103855